Xingze Capital
杏泽资本
elsewhere's corpus doesn't carry a standalone profile of Xingze Capital (杏泽资本) — no founding date, team, or fund size is covered. What the material does show is its activity as a biotech co-investor: it followed on in Vivatides Therapeutics' $54 million Series A (co-led by Qiming Venture Partners, per Qiming's announcement in April 2026) , joined B Capital and Shunxi Fund in Weitao Biotech's 100M+ RMB angel round led by Qiming in late 2025 , and participated in QLT Biotherapeutics' 500M+ RMB Series C alongside 5Y Capital and others in March 2026 . The pattern across these deals — all life-science rounds, typically alongside Qiming — suggests a healthcare-focused fund, but elsewhere's corpus doesn't cover the firm beyond these appearances.
AI-generated — may contain errors, please verify.
Coverage
Vivatides Therapeutics Oversubscribes $54 Million Series A, Co-Led by Qiming Venture Partners
An international innovative biopharmaceutical company focused on the R&D of extrahepatic-targeted small nucleic acid drugs
5Y News｜Aikelian Biotechnology Completes $68.7 Million Funding Round
Aikelian Biotech has successfully completed an oversubscribed $68.7 million funding round.
5Y News | QLT Biotherapeutics Raises Over 500 Million RMB in Series C Funding
Zhitai Biotech Closes Over 500 Million Yuan Series C Round to Accelerate Core Clinical Pipeline Development
BlueRun Ventures Continues to Double Down as QLT Biotherapeutics Closes Over RMB 500 Million Series C Round | BlueRun Family
Accelerate core clinical pipeline development
Morning Star | Weitao Biotech Raises Over 100 Million Yuan in Angel Round Led by Qiming Venture Partners
Innovative companies in the global in vivo cell therapy space
